Satiogenix™

Early-stage wearable platform

Non-chemical appetite regulation.

We are translating a patented, non-invasive hunger-control method into a scalable wearable and validating appetite regulation with modern measurement.

Pre-commercial. Research and development stage.

The problem

Pharmacological appetite control is effective, but it carries cost, dependency, and access friction. A large segment of the market wants non-chemical options that are consistent and measurable.

Our posture

We are not a program. We are not a supplement. We are building infrastructure: a device-led, data-generating system for appetite regulation.

The insight

A proprietary stimulation approach has been refined through decades of real-world practice, applied at scale, and protected by issued intellectual property. The method has been used across more than 400,000 client applications over 30+ years of nationwide practice. The opportunity now is translation: engineering the signal into repeatable hardware parameters and validating outcomes with modern study design.

Patented foundation. Exclusively licensed to Satiogenix.

What we are building

Read the approach →

Collaborate

We are assembling a small group of domain experts to pressure-test translation, clinical validation, and regulatory posture.

  • Wearable and device architecture
  • Obesity medicine and neuroendocrinology
  • Regulatory and claims strategy

Time-boxed advisory sprints. Equity-based.

Email to collaborate

Invest

If you invest in wearables, biofeedback, or metabolic health, we can share our validation plan, technical roadmap, and IP posture.

  • Pre-seed formation
  • Validation roadmap and milestones
  • IP and licensing summary available

Detailed technical materials available under NDA.

Email to invest

Contact

For collaborations, diligence, or introductions: hello@satiogenix.com

Satiogenix™ is an early-stage R&D company. Nothing on this site is medical advice or a consumer offering.